- Active, not recruiting
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma
Updated: Feb 10
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.
Sponsor
Multiple locations
International study
ClinicalTrials.gov Identifier: NCT04244656
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects With Relapsed or Refractory Multiple Myeloma
First Posted : January 28, 2020
Click here for details on ClinicalTrials.gov
Biological: CTX120
CRISPR/Cas9 gene-edited allogeneic anti-BCMA CAR-T cells CTX120
allogeneic CRISPR-Cas9 engineered anti-BCMA T cells CTX120
CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
Description: CTX120 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting BCMA in development for the treatment of multiple myeloma
Gene editing approach: Disruption and insertion
- Multiple locations
- Illinois: University of Chicago
- Pennsylvania: University of Pennsylvania Philadelphia
- Tennessee: Sarah Cannon Research Institute Nashville
Locations
United States, Illinois
United States, Oregon
United States, Pennsylvania
United States, Tennessee
Canada, Ontario
Australia, New South Wales
Australia, Victoria
Spain